Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma has published its unaudited Q3 and 9-month FY26 results (ended December 31, 2025) in leading newspapers, as required by SEBI listing rules. On a consolidated 9-month basis, total income grew 15% year-on-year to ₹73,248.81 lakh, while profit before tax surged 42% to ₹14,463.93 lakh and net profit rose to ₹9,772.90 lakh from ₹7,360.27 lakh last year. Consolidated EPS for 9 months stood at ₹8.86 versus ₹6.55. However, on a standalone Q3 basis, revenue softened to ₹17,491.31 lakh from ₹20,381.71 lakh in the previous quarter, with net profit at ₹1,860.71 lakh versus ₹2,479.19 lakh. The Board declared a 50% interim dividend (₹0.50 per share of Re 1 face value) with February 18, 2026 as the record date.
Strong 9-month consolidated growth and a confirmed interim dividend are positives for shareholders, but the sequential dip in standalone Q3 revenue and profits may raise short-term concerns about standalone business momentum. Overall, the consolidated picture remains healthy.